Key result
Metabolic syndrome is linked to ~7-fold higher prevalence of subclinical left ventricular diastolic dysfunction.
Why the study?
The prevalence of subclinical left ventricular diastolic dysfunction in patients with metabolic syndrome and its relation to metabolic syndrome components in the west region of the Republic of Macedonia are scarce.
Cross-Sectional (n=550)
Yes
Answers are grounded in this paper and cite their sources.
May support screening for subclinical diastolic dysfunction in metabolic syndrome; leaves open need for prospective outcome trials.
Background: Metabolic Syndrome (MetS) has been associated with subclinical changes in cardiac structure and function, including left ventricular diastolic dysfunction (LVDD) and is strong risk factors for the future development of clinical heart failure and specifically increases the risk of heart failure with preserved ejection fraction. To date, the evidence on the prevalence of subclinical LVDD in patient with MetS and relation to components of the MetS, in west region of the Republic of Macedonia are scarce.
No takes yet. Share an insight, caveat, or question.
Ylber Jani (2018) conducted a cross-sectional in Metabolic Syndrome (n=550). Metabolic Syndrome vs. Controls without Metabolic Syndrome was evaluated on Prevalence of subclinical left ventricular diastolic dysfunction (LVDD) grade 1 (p=0.0005). Participants with metabolic syndrome had a higher prevalence of subclinical left ventricular diastolic dysfunction compared to controls without metabolic syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: